- Home
- VSAT vs NVCR Comparison
VSAT vs NVCR Comparison
Compare VSAT & NVCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VSAT
- NVCR
- Stock Information
- Founded
- VSAT 1986
- NVCR 2000
- Country
- VSAT United States
- NVCR Jersey
- Employees
- VSAT N/A
- NVCR N/A
- Industry
- VSAT Radio And Television Broadcasting And Communications Equipment
- NVCR Medical/Dental Instruments
- Sector
- VSAT Technology
- NVCR Health Care
- Exchange
- VSAT Nasdaq
- NVCR Nasdaq
- Market Cap
- VSAT 2.4B
- NVCR 1.8B
- IPO Year
- VSAT 1996
- NVCR 2015
- Fundamental
- Price
- VSAT $10.38
- NVCR $17.39
- Analyst Decision
- VSAT Buy
- NVCR Buy
- Analyst Count
- VSAT 7
- NVCR 5
- Target Price
- VSAT $21.14
- NVCR $26.60
- AVG Volume (30 Days)
- VSAT 1.8M
- NVCR 1.3M
- Earning Date
- VSAT 11-06-2024
- NVCR 10-30-2024
- Dividend Yield
- VSAT N/A
- NVCR N/A
- EPS Growth
- VSAT N/A
- NVCR N/A
- EPS
- VSAT N/A
- NVCR N/A
- Revenue
- VSAT $4,630,427,000.00
- NVCR $549,964,000.00
- Revenue This Year
- VSAT $8.43
- NVCR $16.23
- Revenue Next Year
- VSAT $3.27
- NVCR $6.09
- P/E Ratio
- VSAT N/A
- NVCR N/A
- Revenue Growth
- VSAT 67.71
- NVCR 8.33
- 52 Week Low
- VSAT $9.98
- NVCR $10.87
- 52 Week High
- VSAT $29.11
- NVCR $24.74
- Technical
- Relative Strength Index (RSI)
- VSAT 36.14
- NVCR 43.24
- Support Level
- VSAT $10.10
- NVCR $15.61
- Resistance Level
- VSAT $10.65
- NVCR $17.31
- Average True Range (ATR)
- VSAT 0.49
- NVCR 1.29
- MACD
- VSAT 0.10
- NVCR 0.05
- Stochastic Oscillator
- VSAT 23.60
- NVCR 11.59
About VSAT ViaSat Inc.
Viasat Inc provides bandwidth technologies and services in three segments: satellite services: which provides satellite-based high-speed broadband services to consumers, enterprises, and commercial airlines; commercial networks: which develops end-to-end communication and connectivity systems; and government systems: which produces network-centric Internet Protocol-based secure government communication systems. A large majority of the firm's revenue is generated in the United States, it also has its presence in non U.S. countries.
About NVCR NovoCure Limited
NovoCure Ltd serves in the healthcare sector of the United States. Its business involves the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis and other products and technologies for the treatment of Glioblastoma, Non-smell cell lung cancer and Pancreatic cancer. Geographically, the company derives majority of its revenue from the United States and rest from Germany, Japan and other markets.